Syndax Pharmaceuticals Inc (SNDX) Expected to Announce Quarterly Sales of $380,000.00

Brokerages forecast that Syndax Pharmaceuticals Inc (NASDAQ:SNDX) will post $380,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Syndax Pharmaceuticals’ earnings. Syndax Pharmaceuticals posted sales of $1.19 million in the same quarter last year, which suggests a negative year over year growth rate of 68.1%. The business is scheduled to issue its next earnings report on Monday, March 4th.

On average, analysts expect that Syndax Pharmaceuticals will report full-year sales of $1.66 million for the current year, with estimates ranging from $1.50 million to $2.11 million. For the next year, analysts forecast that the business will report sales of $1.63 million, with estimates ranging from $1.40 million to $2.11 million. Zacks’ sales calculations are an average based on a survey of analysts that cover Syndax Pharmaceuticals.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Monday, November 5th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 91.11% and a negative net margin of 3,185.75%.

A number of brokerages recently issued reports on SNDX. Zacks Investment Research lowered Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, September 13th. ValuEngine lowered Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. HC Wainwright lowered their price target on Syndax Pharmaceuticals to $23.00 and set a “buy” rating for the company in a report on Friday, October 26th. Citigroup lowered their price target on Syndax Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, October 11th. Finally, Morgan Stanley lowered Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 price target for the company. in a report on Monday, October 29th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.20.

Institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company increased its holdings in shares of Syndax Pharmaceuticals by 266.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 10,566 shares of the company’s stock worth $151,000 after buying an additional 7,686 shares during the last quarter. Rhumbline Advisers acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at approximately $103,000. DRW Securities LLC acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at approximately $105,000. Claraphi Advisory Network LLC acquired a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at approximately $129,000. Finally, Bank of America Corp DE increased its holdings in Syndax Pharmaceuticals by 1,382.0% in the 2nd quarter. Bank of America Corp DE now owns 28,084 shares of the company’s stock valued at $197,000 after purchasing an additional 26,189 shares during the last quarter. Institutional investors own 64.38% of the company’s stock.

Shares of NASDAQ SNDX traded down $0.03 during trading hours on Tuesday, reaching $5.44. The stock had a trading volume of 1,300 shares, compared to its average volume of 422,670. The firm has a market capitalization of $129.89 million, a price-to-earnings ratio of -1.88 and a beta of 2.63. Syndax Pharmaceuticals has a 52-week low of $4.36 and a 52-week high of $15.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

Recommended Story: Initial Public Offering (IPO)

Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply